Market Cap 264.57M
Revenue (ttm) 0.00
Net Income (ttm) -39.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.04
Volume 732,200
Avg Vol 684,444
Day's Range N/A - N/A
Shares Out 53.23M
Stochastic %K 72%
Beta 1.71
Analysts Strong Sell
Price Target $15.57

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washing...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 210 2217
Address:
22722 29th Dr. SE, Suite 100, Bothell, United States
bobtheknob
bobtheknob Jan. 7 at 4:41 AM
$ACHV clean break of $5.80-6 and next major resistance is $8.80-9
0 · Reply
leshgo
leshgo Jan. 7 at 12:20 AM
$ACHV 🟢 Strategic Business and Industry Trends Deal-making has rebounded strongly. After a lull, 2025 saw a wave of mega-mergers and licensing agreements. By mid-2025 the total value of biotech M&A already exceeded all of 2024. Big Pharma’s patent cliffs (over 200 drugs losing exclusivity in coming years) are driving many blockbuster acquisitions. For example, J&J paid $14.6 billion for Intra-Cellular, Merck spent $10 billion on Verona Pharma, and Sanofi acquired Blueprint Medicines for $9.5 billion. In 2026 this trend looks set to continue: companies prefer buying late-stage pipelines than taking development risk, often targeting startups with clean IP and regulatory clarity. Such “bio-buying” strategies are shifting portfolios, especially in oncology, rare disease and metabolic disease. https://biopharmaapac.com/news/18/7395/26-key-trends-shaping-biotech-and-life-sciences-in-2026.html?hl=ko-KR
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Jan. 7 at 12:20 AM
$ACHV Here is the raw data on the "Option Size" (Open Interest) for the upcoming months. This proves exactly why the pressure drops off a cliff after next week. January 16, 2026 Strike: $5.00 Open Interest (OI): ~2,350 Call Contracts This is where the Market Maker must pin ACHV at $4.99 to avoid paying out on 235k shares. This is the magnet. February 20, 2026 There is almost no open interest here yet. Because the MMs haven't sold a significant number of options for February, they have zero incentive to manipulate the price. If the stock rips to $7.00, they don't lose a dime. The "Magnet" is turned off. March 20, 2026 Traders haven't started positioning for the "Pre-PDUFA" run in the options market yet; they are likely buying common stock instead. Again, no magnet. Summary of the "Magnet" Schedule Right Now (Jan 6–16): High Pressure. The MM is trapped and fighting to kill the Jan 16 calls. Jan 20 – Mar 20: Zero Pressure. The MM has no "book" to defend. They will let the stock float freely.
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Jan. 6 at 11:09 PM
$ACHV Todays price action wasn’t a sell off or short attack . Its Market Makers. They care about exactly one penny… the one between $4.99 and $5.00. They sold/shorted shares today because they’ve sold a mountain of $5.00 call options to retail traders. If ACHV closes at $5.01 on 1/16 those options are "In The Money." The MM effectively loses; they have to deliver shares or hedge aggressively, which costs them millions. But if they can force the price down to $4.99, every single one of those $5.00 calls expires worthless. They keep 100% of the premium you paid them and owe you nothing. That volume today was MM algorithms stepping in front of real buying pressure, absorbing the demand, and shorting it specifically to protect that $5.00 level. They aren't "investing." They are defending their payout. $4.99 is simply the price where they win and the call holders lose. That is why it happened. It is also bullish that all their effort today closed it exactly on the line… Buyers were there
1 · Reply
V106GuY
V106GuY Jan. 6 at 10:40 PM
$ACHV are they trying to drive this down ahead of any deal? Looks like it
1 · Reply
leshgo
leshgo Jan. 6 at 10:19 PM
$ACHV Hunterbrook and H.C. Wainwright slowly started to heat up the mood. I think there's a good chance that close conversations with big pharma will come and go at the JPMorgan Healthcare conference. I hope to partner with mega pharma from Pfizer, GSK and more.
0 · Reply
V106GuY
V106GuY Jan. 6 at 6:24 PM
$ACHV https://x.com/i/status/2008605424488955982
1 · Reply
Ghostrider2020
Ghostrider2020 Jan. 6 at 5:36 PM
$ACHV If it prints at 5.50 then all it has to do is make it to 6...off to the double digits. 🤩
1 · Reply
Xbagholder
Xbagholder Jan. 6 at 4:47 AM
$ACHV $ALT $CLSK $SLS $SNSE $120 stock price for Cleanspark
2 · Reply
Stock_Catcher
Stock_Catcher Jan. 6 at 2:08 AM
Money Tuesday Watchlist Pt. 3 $SLS $ALT $ACHV $SNSE $CLSK $ Let's Find a 1000% Runner Soon 📈
1 · Reply
Latest News on ACHV
bobtheknob
bobtheknob Jan. 7 at 4:41 AM
$ACHV clean break of $5.80-6 and next major resistance is $8.80-9
0 · Reply
leshgo
leshgo Jan. 7 at 12:20 AM
$ACHV 🟢 Strategic Business and Industry Trends Deal-making has rebounded strongly. After a lull, 2025 saw a wave of mega-mergers and licensing agreements. By mid-2025 the total value of biotech M&A already exceeded all of 2024. Big Pharma’s patent cliffs (over 200 drugs losing exclusivity in coming years) are driving many blockbuster acquisitions. For example, J&J paid $14.6 billion for Intra-Cellular, Merck spent $10 billion on Verona Pharma, and Sanofi acquired Blueprint Medicines for $9.5 billion. In 2026 this trend looks set to continue: companies prefer buying late-stage pipelines than taking development risk, often targeting startups with clean IP and regulatory clarity. Such “bio-buying” strategies are shifting portfolios, especially in oncology, rare disease and metabolic disease. https://biopharmaapac.com/news/18/7395/26-key-trends-shaping-biotech-and-life-sciences-in-2026.html?hl=ko-KR
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Jan. 7 at 12:20 AM
$ACHV Here is the raw data on the "Option Size" (Open Interest) for the upcoming months. This proves exactly why the pressure drops off a cliff after next week. January 16, 2026 Strike: $5.00 Open Interest (OI): ~2,350 Call Contracts This is where the Market Maker must pin ACHV at $4.99 to avoid paying out on 235k shares. This is the magnet. February 20, 2026 There is almost no open interest here yet. Because the MMs haven't sold a significant number of options for February, they have zero incentive to manipulate the price. If the stock rips to $7.00, they don't lose a dime. The "Magnet" is turned off. March 20, 2026 Traders haven't started positioning for the "Pre-PDUFA" run in the options market yet; they are likely buying common stock instead. Again, no magnet. Summary of the "Magnet" Schedule Right Now (Jan 6–16): High Pressure. The MM is trapped and fighting to kill the Jan 16 calls. Jan 20 – Mar 20: Zero Pressure. The MM has no "book" to defend. They will let the stock float freely.
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Jan. 6 at 11:09 PM
$ACHV Todays price action wasn’t a sell off or short attack . Its Market Makers. They care about exactly one penny… the one between $4.99 and $5.00. They sold/shorted shares today because they’ve sold a mountain of $5.00 call options to retail traders. If ACHV closes at $5.01 on 1/16 those options are "In The Money." The MM effectively loses; they have to deliver shares or hedge aggressively, which costs them millions. But if they can force the price down to $4.99, every single one of those $5.00 calls expires worthless. They keep 100% of the premium you paid them and owe you nothing. That volume today was MM algorithms stepping in front of real buying pressure, absorbing the demand, and shorting it specifically to protect that $5.00 level. They aren't "investing." They are defending their payout. $4.99 is simply the price where they win and the call holders lose. That is why it happened. It is also bullish that all their effort today closed it exactly on the line… Buyers were there
1 · Reply
V106GuY
V106GuY Jan. 6 at 10:40 PM
$ACHV are they trying to drive this down ahead of any deal? Looks like it
1 · Reply
leshgo
leshgo Jan. 6 at 10:19 PM
$ACHV Hunterbrook and H.C. Wainwright slowly started to heat up the mood. I think there's a good chance that close conversations with big pharma will come and go at the JPMorgan Healthcare conference. I hope to partner with mega pharma from Pfizer, GSK and more.
0 · Reply
V106GuY
V106GuY Jan. 6 at 6:24 PM
$ACHV https://x.com/i/status/2008605424488955982
1 · Reply
Ghostrider2020
Ghostrider2020 Jan. 6 at 5:36 PM
$ACHV If it prints at 5.50 then all it has to do is make it to 6...off to the double digits. 🤩
1 · Reply
Xbagholder
Xbagholder Jan. 6 at 4:47 AM
$ACHV $ALT $CLSK $SLS $SNSE $120 stock price for Cleanspark
2 · Reply
Stock_Catcher
Stock_Catcher Jan. 6 at 2:08 AM
Money Tuesday Watchlist Pt. 3 $SLS $ALT $ACHV $SNSE $CLSK $ Let's Find a 1000% Runner Soon 📈
1 · Reply
Stock_Catcher
Stock_Catcher Jan. 6 at 1:40 AM
New Video Out on The Bullish Analysis on $SNSE $SIDU $ALT $ACHV $CLSK and more stocks that can rip! https://www.youtube.com/watch?v=4TAFRRF77XU
1 · Reply
bestdriver7
bestdriver7 Jan. 5 at 8:33 PM
0 · Reply
Sieppo
Sieppo Jan. 5 at 8:00 PM
$ACHV best therapy, best idea... The machine is slowly starting.
0 · Reply
jacksparo
jacksparo Jan. 5 at 6:38 PM
$ACHV Doing great here! Also from my email trading ideas ‼️📈📈!📈
0 · Reply
leshgo
leshgo Jan. 5 at 6:36 PM
$ACHV Achieve Life Sciences (ACHV) Identified as Top Biopharma Prospect for 2026 Key Takeaways: Achieve Life Sciences (ACHV, Financial) is positioned as a top pick for 2026 by H.C. Wainwright in the biopharmaceutical sector. The company focuses on developing cytisinicline for smoking cessation, a treatment already marketed in Europe. Despite a challenging market sentiment, ACHV's strategic focus on large market segments presents potential high-reward opportunities. H.C. Wainwright has highlighted Achieve Life Sciences (ACHV) as one of its leading picks for 2026 within the small- to mid-cap biopharmaceutical sector. Despite notable share price increases in 2025, investor sentiment towards this sector was largely subdued at the year's onset. This suggests that there could be a favorable risk-to-reward ratio, with numerous companies potentially offering substantial returns in 2026.
1 · Reply
V106GuY
V106GuY Jan. 5 at 4:31 PM
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Jan. 5 at 4:11 PM
$ACHV 6 months ago... Imagine where we will be 6 months from now.
3 · Reply
Sieppo
Sieppo Jan. 5 at 4:04 PM
$ACHV according to my male stock astrology, if we push through this 5.2 resistance, next stop might well be 5.6ish. Honestly IMO the sky opens up after it all the way to 10.
0 · Reply
Markstockguy
Markstockguy Jan. 5 at 3:34 PM
$CHUC $XXII $ACHV $KAVL Charlie's Holdings ($CHUC) to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. "We believe Charlie's could become the first Company to demonstrate to the FDA that age-gated flavored vape products are indeed ‘appropriate for the protection of public health.' Such a success would not only be game changing for Charlie's, but also transformational for the entire industry."
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Jan. 4 at 9:29 PM
$ACHV I know we see a lot of conference hype that turns into nothing, but next week at JPM is different. Usually these events are filled with managers to mid level VPs. JPM is the only time the actual CEOs and M&A heads from companies like Pfizer and GSK are physically in the room. You don't frame a buyout with mid level management, you do it with the C-Suite. Achieve is walking in with a loaded hand for the first time. The safety profile is locked, the supply chain is pivoted to active FDA sites, and Hunterbrook just validated the setup. They aren't just doing a generic presentation; they have a suite for private 1-on-1s booked. That is where the real work happens. If volume picks up next week with no news, pay attention. We are five months out from approval. This is exactly when a partner tries to lock up a conditional deal before the price runs in April (ie.. We wont pay $30 today, but we will pay $40 on FDA approval). The silence next week might be the most bullish signal we get.
3 · Reply
Markstockguy
Markstockguy Jan. 4 at 6:54 PM
$ACHV Perhaps a bit corny, but the enthusiasm behind this shareholder-created video and song (below) is real. And POWERFUL. CHUC is the best tobacco harm reduction stock out there. The company is profitable. And growing rapidly. Management knows a TON about FDA rules and regulations, owns tens of millions of shares of the company's common stock, and has a compelling strategic plan (based on huge competitive advantages). With ZERO warrants, no short thesis whatsoever, and plans for a 2026 uplist, CHUC is poised to be one of the best microcap investments for 2026. Do your own due diligence. Thank me later.
0 · Reply
Jbg123
Jbg123 Jan. 4 at 11:01 AM
$ACHV looking to start here 👀
2 · Reply